Ketamine vs Propofol: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.04 | 0.0071 | 0.195 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0417 | 0.00739 | 0.202 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00167 | -0.166 | 0.158 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.96 | 0.0636 | 14.5 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.958 | 0.0565 | 16.2 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with a serious adverse event on Ketamine than on Propofol | 600 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Ketamine | Ketamine induction~Ketamine: Ketamine used for induction | 1 | 25 | EG000 | ClinicalTrials.gov |
| Group 2 | Propofol | Propofol induction~Propofol: Propofol used for induction | 1 | 24 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, serious adverse events | ClinicalTrials.gov |
| Time frame | Surgery to discharge, up to 10 days postoperatively | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction | ClinicalTrials.gov |
| NCT number | NCT02554253 | ClinicalTrials.gov |
| Phases | PHASE2 | ClinicalTrials.gov |
| Conditions | Cognitive Disorders, Delirium, Acute Kidney Injury | ClinicalTrials.gov |
| Interventions | Ketamine, Propofol | ClinicalTrials.gov |
| Lead sponsor | Mayo Clinic | ClinicalTrials.gov |
| Results first posted | 2022-02-15 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02554253?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.